

MRS. LUISA SALAZAR-VIZCAYA (Orcid ID : 0000-0003-0527-0141)

PROF. OLIVIA KEISER (Orcid ID : 0000-0001-8191-2789)

Article type : Original Paper

**On the potential of a short-term intensive intervention to interrupt HCV
transmission in HIV-positive men who have sex with men:
a mathematical modelling study**

Luisa Salazar-Vizcaya^{1*}, Roger D. Kouyos^{2,3*}, Jan Fehr^{2,3}, Dominique Braun^{2,3}, Janne Estill⁴,
Enos Bernasconi⁵, Julie Delaloye⁶, Marcel Stöckle⁷, Patrick Schmid⁸, Mathieu Rougemont⁹,
Gilles Wandeler^{1,4}, Huldrych F Günthard^{2,3}, Olivia Keiser^{4**}, Andri Rauch^{1**} and the Swiss
HIV Cohort Study

¹ Department of Infectious Diseases, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland; ² Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland; ³ Institute of Medical Virology, University of Zurich, Zurich, Switzerland; ⁴ Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland; ⁵ Division of Infectious Diseases, Lugano Regional Hospital, Lugano, Switzerland; ⁶ Infectious Diseases Service, Department of Medicine, University Hospital of Lausanne (CHUV), Switzerland; ⁷ Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland; ⁸ Division of Infectious

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/jvh.12752

This article is protected by copyright. All rights reserved.

Diseases and Hospital Epidemiology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland;⁹

Division of Infectious Diseases, University Hospital Geneva, Geneva, Switzerland.

*The first two authors contributed equally to this manuscript

**The last two authors contributed equally to this manuscript

Running title: Short-term HCV treatment as prevention in MSM

Correspondence to:

Luisa Salazar-Vizcaya:

luisapaola.salazarvizcaya@insel.ch

Tel: + 41 31 632 7738

Fax: + 41 31 632 31 76

Universitätsklinik für Infektiologie

Personalhaus 6

3010 Bern, Switzerland

Abstract

Increasing access to direct-acting antiviral (DAA)-treatment for hepatitis C virus (HCV) infection and decelerating the rise in high-risk behaviour over the next decade, could curb the HCV epidemic among HIV-positive men-who-have-sex-with-men (MSM). **We investigated** if similar outcomes would be achieved by short-term *intensive interventions* like the Swiss-

HCVfree-trial. We used a HCV-transmission model emulating two 12-months *intensive-interventions* combining risk-counselling with 1) universal DAA-treatment (*pangenotypic intervention*) and 2) DAA-treatment for HCV-genotypes 1 and 4 (replicating the *Swiss-HCVfree-trial*). To capture potential changes outside *intensive-interventions*, we varied time from HCV-infection to treatment in clinical-routine and overall high-risk behaviour among HIV-positive MSM. **Simulated prevalence dropped** from 5.5% in 2016 to $\leq 2.0\%$ over the intervention period (June/2016-May/2017) with the *pangenotypic-intervention*, and to $\leq 3.6\%$ with the *Swiss-HCVfree-trial*. Assuming time to treatment in clinical-routine reflected reimbursement restrictions (METAVIR $\geq F2$, 16.9 years) and stable high-risk behaviour in the overall MSM population, prevalence in 2025 reached 13.1% without *intensive intervention*, 11.1% with the *pangenotypic intervention* and 11.8% with the *Swiss-HCVfree-trial*. If time to treatment in clinical-routine was 2 years, prevalence in 2025 declined to 4.8% without *intensive-intervention*, to 2.8% with the *pangenotypic intervention*, and to 3.5% with the *Swiss-HCVfree-trial*. In this scenario, the *pangenotypic intervention* and the *Swiss-HCVfree-trial* reduced cumulative (2016-2025) treatment episodes by 36% and 24% respectively. **Therefore**, *intensive interventions* could reduce future HCV-treatment costs and boost the benefits of long-term efforts to prevent high-risk behaviour and to reduce treatment delay. But if after *intensive interventions* treatment is deferred until F2, short-term benefits of *intensive interventions* would dissipate in the long-term.

Key words: Men who have sex with men; Hepatitis C virus; HIV; Direct-acting antivirals; treatment as prevention.

Abbreviations: HCV, hepatitis C virus; MSM, men who have sex with men; DAA, direct-acting antivirals

INTRODUCTION

Hepatitis C virus (HCV) is increasingly transmitted among HIV-positive men who have sex with men (MSM), engage in high-risk sexual practices and do not identify themselves as intravenous drug users(1-6).

We and others have shown that reductions in high-risk practices associated with HCV transmission combined with widespread use of direct-acting antivirals (DAA)-based HCV treatment could reduce HCV-incidence and prevalence (7, 8). In some countries including Switzerland, universal HCV treatment for HIV-positive MSM is not possible because DAA-based HCV treatment is only reimbursed for patients who reached METAVIR stage F2 or in rare instances, in patients with clear extrahepatic manifestations of HCV disease.

An intensive, short-term intervention (referred to as *intensive intervention*) that prevents transmission through risk counseling and provides early DAA-based HCV treatment, could help combat the HCV epidemic among HIV-positive MSM. An intervention of this type is ongoing in the Swiss HIV Cohort Study (SHCS) (9): the *Swiss-HCVree-trial* (NCT02785666). The primary outcomes of this trial are safety and efficacy of the study drugs. Active HCV testing preceded this trial and all patients infected with replicating HCV genotypes 1 or 4 were offered treatment and risk counseling. To what extent *intensive interventions* like the *Swiss-HCVree-trial* can influence the epidemic is however uncertain.

In this modeling study, we assessed the potential to interrupt HCV transmission among HCV-positive MSM of the *Swiss-HCVree-trial* and a similar *intensive intervention* where all HCV genotypes could be treated. This hypothetical intervention will be referred to as *pangenotypic-intervention* and aims to provide more generalizable estimates of the potential of such interventions. We projected HCV prevalence, incidence, genotype distribution and cumulative number of treatment episodes without and with such *intensive interventions*. Projections

assumed different scenarios outside *intensive interventions*. These scenarios included a range of treatment rates in the clinical-routine reflecting regulatory drug restrictions as well as different trends in high-risk behaviour in the overall HIV-positive MSM population.

MATERIALS AND METHODS

The Swiss-HCVree-trial

The Swiss-HCVree-trial is a phase III, multi-center, open-label trial taking place between June 2016 and May 2017 in the SHCS. In preparation for the trial, intensified HCV-PCR based testing of all MSM participating in the cohort took place between October 2015 and May 2016. All patients infected with replicating HCV genotypes 1 or 4 were offered treatment with the study drugs grazoprevir/elbasvir \pm ribavirin. The study drugs were prescribed from June 2016 to February 2017 independently of reimbursement restrictions. The *Swiss-HCVree-trial* was restricted to HCV genotypes 1 or 4 because grazoprevir/elbasvir is not sufficiently active against HCV genotypes 2 and 3 [which account for 12% of all infections (10)]. In addition to HCV treatment, enrolled patients who reported inconsistent condom use with occasional partners (a marker for high-risk behaviour) and provided their consent to a behavioural intervention received 45-minute sessions of individual risk counseling at weeks 4, 6, 8, and 12.

Mathematical model of an intensive intervention

To simulate the effect of *intensive interventions*, we extended a previously developed model of HCV transmission among HIV-positive MSM in Switzerland(7). The model uses a system of ordinary differential equations where the population is classified into 24 compartments

defined by *i*) stage of HCV infection (uninfected, infected, and on treatment); *ii*) HCV genotype (1 or 4 and 2 or 3); *iii*) risk behaviour (with and without high-risk practices associated with HCV transmission); *iv*) enrolment in HIV-care; and *v*) enrolment in the *intensive intervention*. The model assumes that a fraction of patients reporting condomless anal sex with occasional partners also engage in practices associated with HCV transmission. Model parameters are described in Table 1 and Supplementary Table S1.

Figure 1 qualitatively depicts the redistribution of the population upon introduction and completion of an *intensive intervention*.

Model parameterization was fully based on estimates previous to the start of the *Swiss-HCVfree-trial*.

Rules inside the intensive interventions

Rules in common between the *pangenotypic intervention* and the *Swiss-HCVfree-trial*.

The model matches the testing period of the *Swiss-HCVfree-trial*. Enrolled individuals are treated with DAAs for 12 weeks. Because high-risk behaviour is likely to be underreported (11), and risk counselling is not 100% effective (12), the model assumed that intensified risk counselling within the *intensive interventions* had an effectiveness of 50% i.e., risk counselling led to 50% of patients with high-risk behaviour at enrolment in the *intensive interventions* to permanently stop this behaviour. Of note, individuals are assumed to become susceptible to reinfection after HCV clearance regardless of ongoing *intensive interventions*.

Differences between the *pangenotypic intervention* and the *Swiss-HCVree-trial*.

HCV-test and treatment took place in HIV-positive MSM enrolled in HIV-care for simulations with the *pangenotypic intervention* and in those enrolled in the SHCS for simulations with the *Swiss-HCVree-trial*. Of note, we estimated that the SHCS included 84% of all HIV-positive MSM in Switzerland (13) (14). Patients enrolled in the *pangenotypic intervention* infected with **all genotypes** were treated within 3 months since the beginning of the intervention. Analogously, in the *Swiss-HCVree-trial* patients infected with **genotypes 1 or 4** were treated within 9 months from the beginning of the trial.

We modeled the following scenarios for patients not enrolled in *intensive interventions* and for everyone after the completion of the intervention:

Scenarios outside intensive interventions

Treatment in clinical-routine. We assumed HCV treatment outside *intensive interventions* or in absence of *intensive interventions* (Figure 1) to be DAA-based resulting in 95% sustained virological response (SVR) (15). Treatment rates were chosen to reflect the (mean) time from HCV infection to treatment start corresponding to four different scenarios of clinical-routine: *i*) mean time from HCV infection to F2 in the METAVIR scale (16.9 years, labeled F2 scenario) (16), reflecting the current reimbursement restriction in Switzerland and other countries); *ii*) mean time from HCV infection to F1 in the METAVIR scale [8.2 years, labeled F1 scenario)] (16); *iii*) 2 years; and *iv*) 1 year.

High-risk behavior in the overall (HIV-positive MSM) population. We considered two main scenarios where the fraction of individuals engaging in high-risk practices associated with HCV transmission: 1) remained stable at the value estimated for 2016 (14%, labeled stable

high-risk behaviour) or 2) declined continuously to reach a 50% reduction by 2025 (labeled reduced high-risk behaviour).

Projections on the effect of intensive interventions

The overall projection period was 2016-2025. Based on the scenarios depicted above, we reported trajectories, short-term (end-of-intervention, i.e., May 2017) and long-term (2025) HCV prevalence, incidence, genotype distribution and cumulative number of treatment episodes.

We undertook independent analyses that assumed *i)* no *intensive intervention*; *ii)* the *pangenotypic intervention*; and *iii)* the *Swiss-HCVree-trial*. We only projected genotype distribution with the *Swiss-HCVree-trial* (since treatment is subtype-independent in *i* and *ii*). All these projections correspond to HIV-positive MSM living in Switzerland, including those who are not enrolled in HIV-care.

Projections with the *Swiss-HCVree-trial* restricted to SHCS participants. To allow validation of these results with SHCS data in the future, we also reported separate model projections with the *Swiss-HCVree-trial* restricted to the subset of modeled individuals enrolled in the SHCS.

Sensitivity analyses

We undertook three sensitivity analyses for MSM enrolled in the SHCS. These analyses assumed: I) further increase in high-risk behaviour in the overall population; II) larger fraction of HCV infections acquired by contacts outside the modeled population; and III) higher efficacy of risk counseling interventions within the *Swiss-HCVree-trial*.

Table 1 describes the model parameters associated with all scenarios including sensitivity analyses.

RESULTS

At the beginning of the screening period 4,257 MSM were enrolled in the SHCS. Simulated HCV prevalence and incidence at the beginning of the trial were 5.8% and 2.6 per 100 person-years respectively. Further characteristics of the modelled population are described in detail in (7, 10).

Projections on the effect of the pangenotypic intervention

End-of-intervention projections (Figure 2). Without *intensive intervention*, assuming stable risk behaviour and under the current reimbursement restrictions (F2 scenario), simulated HCV prevalence increased from 5.6% (in June 2016) to 7.7% in mid-2017. But by the end of the *pangenotypic intervention* (May 2017), simulated prevalence had declined to <2.0% across all scenarios of treatment rate in clinical-routine and high-risk behaviour in the overall population. Of note, if time from HCV infection to treatment in the overall population was <2 years, by May 2017, the model also predicted a decline in prevalence even without *intensive intervention*. Little differences between the two scenarios of high-risk behaviour in the overall population were observed in these short-term simulations.

Long-term projections (2025)(Figure 3A). If we assumed stable high-risk behaviour in the overall population, expected prevalence in 2025 **without** *intensive interventions* ranged from 13.1% to 0.7% across scenarios of treatment rate in clinical-routine. The long-term effect of the *pangenotypic intervention* was smaller than that at the end of the intervention. This occurred because after the intervention period, HCV-prevalence increased again. The speed of this increase was determined by treatment rate in clinical-routine and high-risk behaviour in

This article is protected by copyright. All rights reserved.

the overall population. These variables also influenced the absolute reduction in long-term prevalence following the *pangenotypic intervention*, which ranged between 0.1 and 2.0 percent points. If high-risk behavior in the overall population remained stable and treatment in clinical-routine was deferred according to the current reimbursement restriction (F2 scenario), simulated HCV-prevalence in 2025 exceeded that in 2016 by at least 5 percent points **with or without** *intensive interventions*. But if time from HCV infection to treatment in clinical-routine was < 2 years, simulated prevalence in 2025 was lower than that in 2016. If time from HCV infection to treatment in clinical-routine was 2 years, the *pangenotypic intervention* reduced expected prevalence by 41% (from 4.8% without *pangenotypic intervention* to 2.8%) and 42% (from 1.6% to 0.9%) when assuming stable and reduced high-risk behaviour in the overall population respectively.

When time from HCV infection to treatment in clinical-routine was one year, HCV-prevalence dropped to <0.7%.

Cumulative number of treatment episodes (2016-2025)(Figure 3B). In the F2 scenario, the *pangenotypic intervention* increased the cumulative number of treatment episodes by 35% (from 214 to 288) when assuming stable high-risk behaviour in the overall population (Figure 3B). But with much shorter time from HCV infection to treatment in clinical-routine, the *pangenotypic intervention* was predicted to reduce treatment episodes with respect to *no intensive intervention*. For instance, if time from HCV infection to treatment in clinical-routine was 2 years and high-risk behaviour in the overall population stable, the *pangenotypic intervention* reduced the cumulative number of treatment episodes by 36% (from 678 to 431).

Projections on the effect of the Swiss-HCVree-trial

Model projections with the *pangenotypic intervention* and those with the *Swiss-HCVree-trial* were close (Supplementary Figures S1 and S2). However, as expected, the *Swiss-HCVree-trial* was less effective at reducing HCV-prevalence and treatment episodes than the *pangenotypic intervention*. These results are reported in detail in the Supplementary Material.

In all scenarios, reduced high-risk behaviour in the overall population was more successful than either the *pangenotypic intervention* or the *Swiss-HCVree-trial* at reducing HCV-prevalence in the long-term (Figure 3 and Supplementary Figure S2A).

Expected trajectories of HCV-prevalence, -incidence and genotype distribution with the Swiss-HCVree-trial

Figure 4 and Supplementary Figure S3 display simulated HCV-prevalence, genotype distribution and incidence over the projection period without *intensive intervention* and with the *Swiss-HCVree-trial*. Here we set time from HCV infection to treatment in clinical-routine to reflect the F2 scenario and to 2 years. These figures illustrate the trajectories towards the time points reported in Figures 2, 3A and Supplementary Figures S1 and S2A.

If we combined stable high-risk behaviour in the overall population with the F2 scenario (Figure 4A and Supplementary Figure S3A), **prevalence** and **incidence** dropped to <3.6% and <1.3/100 person-years (from an incidence of 2.4 person-years in 2016) respectively over the intervention period. But prevalence and incidence rose again when the intervention ended. However, if mean time from HCV infection to treatment in clinical-routine was 2 years, **prevalence** and **incidence** dropped and remained low even after the completion of the trial (Figure 4A and Supplementary Figure S3A).

Accepted Article

Reduced high-risk behaviour in the overall population led to similar outcomes (Figure 4B and Supplementary Figure S3B). But as expected, the post-intervention speeds of increase in prevalence and incidence were much lower in this case.

In the F2 scenario, simulated incidence with the *Swiss-HCVree-trial* surpassed that without *intensive intervention* in mid-2019 and remained slightly above until the end of the projection period (Supplementary Figure S3).

Because only patients infected with genotypes 1 or 4 are enrolled in the *Swiss-HCVree-trial*, a comparative advantage for the spread of genotypes 2 and 3 is imminent. Figures 4C and 4D show the projected **genotype distribution** when assuming stable and reduced high-risk behaviour in the overall population.

In the F2 scenario, the proportion of infections with genotypes 2 or 3 increased from 11% in 2016 to up to 27% in 2025. Earlier HCV treatment in clinical-routine led to smaller changes in genotype distribution (Figures 4C and 4D). This occurs because treatment in clinical-routine is homogeneous across genotypes. Early treatment therefore shirks the discrepancy between genotypes imposed by the *Swiss HCV trial*.

Projections with the *Swiss-HCVree-trial* restricted to SHCS participants: Supplementary Figures S4 to S7 show model projections for MSM enrolled in SHCS. As expected, these results were very close to those obtained in the main analyses (Figures 2 to 4 and Supplementary Figures S1 to S3).

Supplementary Table S2 summarizes key simulation outcomes.

Sensitivity analyses

The outcomes of the sensitivity analyses are reported in the supplementary material. The projected effects of the *Swiss-HCVree-trial* remained qualitatively unchanged (Supplementary Figures S4 to S7).

DISCUSSION

Principal findings

Our results suggest that *intensive interventions* can reduce HCV prevalence among HIV-positive MSM. Simulated prevalence dropped below 2.0% (from 5.5% in 2016) over the intervention period with the *pangenotypic intervention* and below 3.6% with the *Swiss-HCVree-trial*. But prevalence would only remain low after *intensive interventions* if reimbursement limitations (METAVIR>F2) are retracted so that treatment outside *intensive interventions* can start much earlier after HCV diagnosis. Reductions in prevalence by year 2025 due to *intensive interventions* ranged between 10% and 41%. *Intensive interventions* also reduced the projected number of treatment episodes when time from HCV infection to treatment was <2 years. If we assumed stable high-risk behaviour in the overall population, the percentage of averted treatment episodes reached 36% and 24% with the *pangenotypic intervention* and with the *Swiss-HCVree-trial* respectively.

If time from HCV infection to treatment in the clinical-routine was reduced to < 2 years, prevalence would decrease steadily even without *intensive interventions*. When time from HCV infection to treatment in clinical-routine was 1 year, the estimated effect of *intensive interventions* was negligible. This occurs because treatment rate in clinical-routine and within the *intensive intervention* are very similar in this case. This high treatment rates result in basic

reproduction numbers smaller than 1 independently of *intensive interventions*. Prevalence and incidence in this situation are therefore low ($<0.7\%$ and $<0.4/100\text{py}$ respectively in 2025).

High costs of DAA remain a major barrier to treatment. A recent study estimated prices of DAA therapy adjusted for purchasing power parity ranging between 1,861 USD and 154,227 USD (17). Independently of *intensive interventions*, reducing time from HCV infection to treatment in the clinical-routine to 1 year would at most double the cumulative number of treatment episodes between 2016 and 2025 while decreasing prevalence by at least a factor of 18 over the same period. In particular, reducing time from HCV infection to treatment in clinical-routine from the scenario F2 to 1 year, combined with an *intensive intervention* would only increase the number of treatments by 20% by 2025. Therefore, more aggressive treatment and the relief of reimbursement restrictions could substantially reduce HCV transmission at relatively low additional costs in the long-term. The model also suggests that if treatment reimbursement restrictions remain (METAVIR $>F2$), the *Swiss-HCVfree-trial* would increase by at least 33% the cumulative number of treatments between 2016 and 2025 in Switzerland.

A sensitivity analysis where we increased the effectiveness of risk counselling within the *Swiss-HCVfree-trial* resulted in a modest reduction in long-term prevalence (<0.54 percent points by 2025). By contrast, sustained reductions in high-risk behaviour in the overall population, could rapidly curb the epidemic even without increasing access to treatment. This underscores the importance of sustained efforts to prevent exposure to HCV transmission. But long-lasting reductions in high-risk behaviour are hard to achieve in HIV-positive MSM on antiretroviral therapy (12). This implies the need for treatment as prevention to accompany behavioural interventions. For instance, if stabilization of high risk-behaviour is achieved, earlier treatment initiation could substantially reduce HCV prevalence.

Strengths and limitations

To our knowledge this is the first published study to use a mathematical model to project the population level impact of a clinical trial or other *intensive interventions* to tackle HCV transmission. The strengths and limitations of the core model have been discussed elsewhere (7). We believe the main strength of the mathematical model developed in the present study is that it emulates the dynamics of sexually transmitted HCV and its response to real-life interventions and to hypothetical scenarios of treatment and high-risk behaviour simultaneously. Moreover, our results could be generalized to other settings as regulatory drug restrictions remain in several countries (18-20) and we provide estimates independent of the particular design of the *Swiss-HCVree-trial* by modelling the *pangenotypic intervention*.

The lack of data on the role of HCV infections acquired through high-risk practices abroad could limit the accuracy of our predictions. While a phylogenetic study provided evidence for dominant domestic transmission in Switzerland (21), more detailed analyses to quantify the relative contributions of domestic and imported transmissions are needed to reach a conclusion on this matter. Nevertheless, a sensitivity analysis suggested that our results are robust to high fractions of infections due to contacts outside the modelled population. Of note, the *Swiss-HCVree-trial* collects data on the presumed place of HCV acquisition and we aim at performing phylogenetic studies to address this open question.

The model assumed that HCV treatment with DAAs lasted for 12 weeks for all patients. In reality grazoprevir/elbasvir treatment is recommended to last for 16 weeks in patients with pre-existing NS5A resistance associated substitutions and in some treatment experienced patients (22). However, less than 10% of all study participants are expected to fulfil these criteria.

Our model neglects factors other than differential treatment rates across genotypes that could influence genotypes distribution (e.g., changes in demographics due to migrations). Therefore we implicitly assumed the genotype distribution to be static in scenarios without the *Swiss-HCVree-trial*.

Finally, because model parameterization only considered data collected before the recruitment period of the *Swiss-HCVree-trial*, recent changes in population characteristics may have been neglected.

Outlook

We aim to assess the accuracy of our model projections by comparing them with the real end-of-study effects of the *Swiss-HCVree-trial*. The core transmission model is largely based on data from the SHCS and was shown to reproduce the epidemic accurately(7). However, comparing model outcomes with real data will help evaluate and improve the extent to which the model structure and underlying assumptions capture the key aspects of the dynamics of sexually transmitted HCV and its response to specific interventions.

Implications of findings

Our model projections suggest that a *1-year intensive intervention* could save HCV treatment costs while boosting the benefits of long-term efforts to prevent high-risk behaviour and to increase treatment rate in clinical-routine. However, if treatment reimbursement restrictions are not relieved and the level of high-risk behaviour in the overall HIV-positive MSM population does not decrease, HCV-prevalence may double by 2025 despite *intensive interventions*.

The results of this study triggered the prolongation of the *Swiss HCVfree trial*. Treatment for patients with reinfection with HCV genotypes 1 and 4 will be provided between March 2017 and January 2018.

Acknowledgments

Authors' contributions: LSV, RDK and AR designed the study. LSV and RDK formulated the mathematical model. LSV implemented the model and performed the model analyses. JF, DB, EB, JD, MS, PS, MR, HFG contributed cohort data. LSV, RDK, JF, DB, JE, HFG, OK and AR drafted the first version of the manuscript which was then revised by all the other authors. All authors contributed to the interpretation of the results.

Statement of interests

Roger D. Kouyos received travel grants from Gilead Sciences; Jan Fehr reports support to his institution for consultancy from Abbvie, Bristol Myers Squibb, Gilead, Janssen, Merck and ViiV, travel grants from Gilead, Janssen, Merck and Pfizer, and personal fees for advisory boards from the Federal Commission for Sexual Health; Andri Rauch reports support to his institution for advisory boards and/or travel grants from Janssen-Cilag, MSD, Gilead Sciences, Abbvie, and Bristol-Myers Squibb, and an unrestricted research grant from Gilead Sciences. All remuneration went to his home institution and not to Andri Rauch personally. Enos Bernasconi reports support to his institution for advisory boards from Gilead Sciences, MSD, BMS, Abbvie, ViiV Healthcare, Janssen, consultancy from Gilead and travel grants from Gilead Sciences, MSD and Abbvie. Marcel Stöckle reports support to his institution for consultancy from Roche and personal fees for board membership from AbbVie, Gilead Sciences, Janssen-Cilag, MSD and ViiV, and travel grants from Gilead Sciences, Janssen-

This article is protected by copyright. All rights reserved.

Cilag and MSD. Patrick Schmid reports support to his institution for advisory boards from Gilead, Abbvie and BMS. Mathieu Rougemont received travel grants from BMS and Gilead. Gilles Wandeler received travel grants from Gilead and MSD. Huldrych F Günthard reports personal fees for consultancy from Gilead Sciences and Merck.

For all authors: all reported financial support was provided outside this study.

Funding

This work was funded by the Swiss National Science Foundation (SNF) [grant numbers 148522 and 146143].

References

1. Hagan H, Jordan AE, Neurer J, Cleland CM. Incidence of sexually transmitted hepatitis C virus infection in HIV-positive men who have sex with men. *AIDS*. 2015;29(17):2335-45.
2. Gotz HM, van Doornum G, Niesters HG, den Hollander JG, Thio HB, de Zwart O. A cluster of acute hepatitis C virus infection among men who have sex with men--results from contact tracing and public health implications. *AIDS*. 2005;19(9):969-74.
3. Wandeler G, Gsponer T, Bregenzer A, Günthard HF, Clerc O, Calmy A, et al. Hepatitis C virus infections in the Swiss HIV Cohort Study: a rapidly evolving epidemic. *Clin Infect Dis*. 2012;55(10):1408-16.
4. Danta M, Brown D, Bhagani S, Pybus OG, Sabin CA, Nelson M, et al. Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours. *AIDS*. 2007;21(8):983-91.
5. Foster AL, Gaisa MM, Hijdra RM, Turner SS, Morey TJ, Jacobson KB, et al. Shedding of Hepatitis C Virus Into the Rectum of HIV-infected Men Who Have Sex With Men. *Clin Infect Dis*. 2016.
6. Kouyos RD, Rauch A, Braun DL, Yang WL, Boni J, Yerly S, et al. Higher risk of incident hepatitis C virus coinfection among men who have sex with men, in whom the HIV genetic bottleneck at transmission was wide. *J Infect Dis*. 2014;210(10):1555-61.
7. Salazar-Vizcaya L, Kouyos RD, Zahnd C, Wandeler G, Battegay M, Darling KE, et al. Hepatitis C virus transmission among human immunodeficiency virus-infected men who have sex with men: Modeling the effect of behavioral and treatment interventions. *Hepatology*. 2016;64(6):1856-69.
8. Martin NK, Thornton A, Hickman M, Sabin C, Nelson M, Cooke GS, et al. Can Hepatitis C Virus (HCV) Direct-Acting Antiviral Treatment as Prevention Reverse the HCV Epidemic Among Men Who Have Sex With Men in the United Kingdom? Epidemiological and Modeling Insights. *Clin Infect Dis*. 2016;62(9):1072-80.
9. Cohort profile: the Swiss HIV Cohort study. *Int J Epidemiol*. 2010;39(5):1179-89.
10. Wandeler G, Rohrbach J, Metzner K, Fehr J, Stöckle M, Cavassini M, et al. Incident HCV Infections in the Swiss HIV Cohort Study: Natural History and Treatment Outcomes. CROI poster # 643 2014.

11. Zenilman JM, Weisman CS, Rompalo AM, Ellish N, Upchurch DM, Hook EW, 3rd, et al. Condom use to prevent incident STDs: the validity of self-reported condom use. *Sex Transm Dis*. 1995;22(1):15-21.
12. Nostlinger C, Platteau T, Bogner J, Buyze J, Dec-Pietrowska J, Dias S, et al. Computer-assisted Intervention for Safer Sex in HIV-Positive Men Having Sex with Men: Findings of a European Randomized Multi-Center Trial. *J Acquir Immune Defic Syndr*. 2015.
13. The EMIS Network. EMIS 2010. The European Men-Who-Have-Sex-With-Men Internet Survey. Findings from 38 countries. Stockholm: European Centre for Disease Prevention and Control 2013. Available from: <http://www.emis-project.eu/final-report>.
14. van Sighem A, Vidondo B, Glass TR, Bucher HC, Vernazza P, Gebhardt M, et al. Resurgence of HIV infection among men who have sex with men in Switzerland: mathematical modelling study. *PLoS One*. 2012;7(9):e44819.
15. Lawitz E, Gane E, Pearlman B, Tam E, Ghesquiere W, Guyader D, et al. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. *Lancet*. 2015;385(9973):1075-86.
16. Thein HH, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. *Hepatology*. 2008;48(2):418-31.
17. Iyengar S, Tay-Teo K, Vogler S, Beyer P, Wiktor S, de Joncheere K, et al. Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis. *PLoS Med*. 2016;13(5):e1002032.
18. Marshall AD, Saeed S, Barrett L, Cooper CL, Treloar C, Bruneau J, et al. Restrictions for reimbursement of direct-acting antiviral treatment for hepatitis C virus infection in Canada: a descriptive study. *CMAJ Open*. 2016;4(4):E605-E14.
19. Barua S, Greenwald R, Grebely J, Dore GJ, Swan T, Taylor LE. Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States. *Ann Intern Med*. 2015;163(3):215-23.
20. NHS England, Thousands more patients to be cured of hepatitis C, <https://www.england.nhs.uk/2015/06/patients-hep-c/> (2015) [Accessed January 06, 2017].
21. Kouyos RD, Rauch A, Boni J, Yerly S, Shah C, Aubert V, et al. Clustering of HCV coinfections on HIV phylogeny indicates domestic and sexual transmission of HCV. *Int J Epidemiol*. 2014.
22. Zepatier Fachinformation des Arzneimittel-Kompendium der Schweiz, Compendium; <http://compendium.ch/mpro/mnr/27206/html/de#7100> [accessed: 12.08.2016].

Table 1. Model parameters associated with the simulated scenarios

Parameter	Value	Rationale
Inside intensive-interventions		
treatment duration (weeks)	12	Standard duration
Time from recruitment to HCV treatment (months)		
<i>Pangenotypic intervention</i>	3	Optimistic assumption
<i>Swiss HCVfree trial</i>	9	As scheduled
Effectiveness of risk counselling interventions*		
<i>Main analyses</i>	50%	Assumption
<i>Sensitivity analysis III</i>	75%	
Outside intensive interventions		
Treatment duration (weeks)	12	Standard duration
Time from HCV infection to treatment in clinical-routine (years)	[1-16.9]	Assumption
Fraction with high-risk behaviour in the overall MSM population		
<i>Main analyses</i>		
<i>Stable at 2016 estimate</i>	0.14**	Assumption
<i>50% reduction (in 2025)</i>	0.07	
<i>Sensitivity analysis I</i>		
<i>50% increase (in 2025)</i>	0.21	
Percentage of imported infections***		
<i>Main analyses</i>	4%	Assumption
<i>Sensitivity analysis II</i>	25%	

*% of patients with high-risk behaviour at enrolment who permanently stop this behaviour; ** Estimated within the model by using the rate of transition to unsafe sex and the proportion of patients with high-risk behaviour at time of HIV infection reported in (7); ***% of all HCV infections that occurred between 2000 and 2013 among MSM enrolled in HIV-care

Supplementary text figures and tables can be found in the Web Appendix

Figure legends

Figure 1. Scheme of the introduction of an intensive intervention.

Simplified representation of the distribution of HIV-positive MSM when an intensive intervention is introduced. The size of the modules do not reflect the actual relative sizes of the subpopulations.

Figure 2. End-of-intervention HCV prevalence projections.

Without intensive-intervention (red and orange bars) and with the pangenotypic intervention (blue bars) assuming stable and reduced high-risk behaviour in the overall HIV-positive MSM population.

The dashed rectangle highlights a common reimbursement restriction.

Figure 3. A) Long-term HCV prevalence, B) Cumulative treatment episodes and C) Percentage of treatment episodes averted between 2016 and 2025 by introducing the pangenotypic intervention.

Without intensive-intervention (red and orange bars) and with the pangenotypic intervention (blue bars) assuming stable and reduced high-risk behaviour in the overall HIV-positive MSM population. Overall risk behaviour refers to high-risk behaviour among HIV-positive MSM.

The dashed rectangle highlights a common reimbursement restriction.

Figure 4. Projected trajectories of HCV A&B) prevalence and C&D) genotype distribution between 2016 and 2025 with and without the Swiss-HCVree-trial.

Assuming stable (left panels) and reduced (right panels) high-risk behaviour in the overall HIV-positive MSM population. Projections assumed standard-of-care mean time from HCV infection to treatment of 16.9 (F2 scenario) and 2 years.







